Savara announces fda response from type c meeting on molgradex for apap development program

Savara announces fda response from type c meeting on molgradex for apap development program.savara inc - fda indicated that data provided in briefing package do not provide sufficient evidence of efficacy and safety.savara inc - remain committed to molgradex development program.savara inc - fda did not recommend that company submit a biologics license application.
SVRA Ratings Summary
SVRA Quant Ranking